Literature DB >> 6191191

3h-substance P binding to salivary gland membranes. Regulation by guanyl nucleotides and divalent cations.

C M Lee, J A Javitch, S H Snyder.   

Abstract

With appropriate measures to protect 3H-substance P (3H-SP) from proteolytic degradation and from nonspecific adsorption to glass-fiber filters, we have been able to demonstrate reliably a high-affinity specific binding of 3H-SP to rat submaxillary/sublingual gland membranes with a KD of 1 nM and Bmax of 6 pmoles/g of tissue. The relative potencies of various SP fragments and related analogues in reducing 3H-SP binding parallel their potencies in stimulating phosphatidylinositol turnover, amylase release, and salivation, thus supporting an association of the observed 3H-SP binding site with the physiological SP receptors in this tissue. This binding is selectively stimulated by some divalent cations (Mn2+ greater than Mg2+ greater than Ca2+) but inhibited by several guanyl nucleotides, suggesting a possible linkage to adenylate cyclase. However, no effect of SP on either the basal or the norepinephrine-stimulated adenylate cyclase activity could be demonstrated in salivary gland homogenates.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6191191

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

1.  Pharmacological properties of a potent and selective nonpeptide substance P antagonist.

Authors:  C Garret; A Carruette; V Fardin; S Moussaoui; J F Peyronel; J C Blanchard; P M Laduron
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

2.  Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist.

Authors:  A Doble; D Girdlestone; O Piot; D Allam; J Betschart; A Boireau; A Dupuy; C Guérémy; J Ménager; J L Zundel
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

3.  Neuropeptide K potently stimulates salivary gland secretion and potentiates substance P-induced salivation.

Authors:  Y Takeda; J E Krause
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Comparative studies on peptides representing the so-called tachykinin-like region of the Alzheimer Abeta peptide [Abeta(25-35)].

Authors:  O M El-Agnaf; G B Irvine; G Fitzpatrick; W K Glass; D J Guthrie
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

5.  Characterization of a tachykinin peptide NK2 receptor transfected into murine fibroblast B82 cells.

Authors:  P L van Giersbergen; S A Shatzer; A K Henderson; J Lai; S Nakanishi; H I Yamamura; S H Buck
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

6.  FR 113680: a novel tripeptide substance P antagonist with NK1 receptor selectivity.

Authors:  H Morimoto; M Murai; Y Maeda; D Hagiwara; H Miyake; M Matsuo; T Fujii
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

7.  Pharmacological profile of a high affinity dipeptide NK1 receptor antagonist, FK888.

Authors:  T Fujii; M Murai; H Morimoto; Y Maeda; M Yamaoka; D Hagiwara; H Miyake; N Ikari; M Matsuo
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

8.  Characterization of NK1 and NK2 tachykinin receptors in guinea-pig and rat bronchopulmonary and vascular systems.

Authors:  A Floch; V Fardin; I Cavero
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

9.  Characterization of tachykinin receptors in isolated basilar arteries of guinea-pig.

Authors:  L Edvinsson; I Jansen
Journal:  Br J Pharmacol       Date:  1987-03       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.